A meta-analysis of over 71,000 patients found that GLP-1 receptor agonists reduced cardiovascular events by 14%, kidney complications by 17%, and death by 12%, with no difference between injectable and oral forms.
12% reduction in all-cause mortalityAcross 71,351 patients in 10 randomized trials of long-acting GLP-1 receptor agonists vs placebo in type 2 diabetes
What the researchers found
Long-acting GLP-1 receptor agonists — both injectable and oral forms — significantly reduced cardiovascular events, heart failure hospitalizations, kidney complications, and death in people with type 2 diabetes. Across 10 randomized trials with over 71,000 participants, GLP-1 RAs reduced major adverse cardiovascular events by 14% (HR 0.86), heart failure hospitalization by 14%, composite kidney outcomes by 17%, and all-cause mortality by 12%.
Critically, there was no significant difference in benefits between subcutaneous (injectable) and oral formulations, and no increased risks of severe hypoglycemia, retinopathy, or pancreatic events were found.
Why it matters
This is the most comprehensive meta-analysis of GLP-1 receptor agonist outcomes to date, incorporating the latest SOUL and FLOW trial data. It definitively establishes that both injectable and oral GLP-1 RAs protect against heart disease, kidney disease, and death — not just lower blood sugar. The finding that oral formulations provide similar benefits to injections is particularly important, as it could dramatically expand patient access to these protective effects.
The numbers in context
n=71,351 · 10 trials · MACE ↓14% (HR 0.86) · HHF ↓14% (HR 0.86) · kidney outcome ↓17% (HR 0.83) · mortality ↓12% (HR 0.88)
How the study worked
The researchers conducted a systematic review of PubMed through February 2025, including all randomized placebo-controlled cardiovascular and kidney outcomes trials of long-acting GLP-1 receptor agonists with at least 500 participants with type 2 diabetes. Data from 10 trials were pooled using a random-effects model to estimate hazard ratios for cardiovascular events, heart failure, kidney outcomes, mortality, and safety endpoints.
Who was studied
Over 71,000 individuals with type 2 diabetes across 10 randomized placebo-controlled outcomes trials
What this study cannot tell us
As a trial-level meta-analysis (rather than individual patient data), detailed subgroup analyses were not possible, and ecological bias may be present. The analysis could not examine whether specific patient populations benefit more than others.
How to read the evidence
This is a systematic review and meta-analysis of 10 large randomized controlled trials — the gold standard of evidence. With over 71,000 participants, robust statistical methods, and low heterogeneity across studies, this represents the highest quality evidence available for GLP-1 receptor agonist outcomes.
When this study was published
Published in 2025, this is the most current comprehensive meta-analysis of GLP-1 receptor agonist outcomes, incorporating the latest SOUL and FLOW trial results through February 2025.
The bigger picture
GLP-1 receptor agonists have evolved from diabetes medications to multi-organ protective therapies. This meta-analysis — the largest and most current to date — confirms that the cardiovascular and kidney benefits of GLP-1 drugs are a class effect, not limited to specific formulations or routes of administration. With oral semaglutide now showing equivalent organ protection to injectables, the barriers to widespread use are falling, potentially transforming how type 2 diabetes is managed worldwide.
Questions still open
- Do GLP-1 receptor agonists provide similar cardiovascular and kidney protection in people without diabetes who use them for weight management?
- Which specific patient subgroups benefit most from GLP-1 therapy — those with existing heart disease, kidney disease, or both?
- Could combining GLP-1 agonists with other peptide-based therapies (like GIP agonists in tirzepatide) offer even greater organ protection?
Common questions
Do oral GLP-1 drugs work as well as injectable ones for protecting the heart and kidneys?
Do GLP-1 drugs cause pancreatic or eye problems?
Read the original research
Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials.
Diabetes care, 48(5), 846-859
Citation
Lee, Matthew M Y; Sattar, Naveed; Pop-Busui, Rodica; Deanfield, John; Emerson, Scott S; Inzucchi, Silvio E; Mann, Johannes F E; Marx, Nikolaus; Mulvagh, Sharon L; Poulter, Neil R; Badve, Sunil V; Pratley, Richard E; Perkovic, Vlado; Buse, John B; McGuire, Darren K. (2025). Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials.. Diabetes care, 48(5), 846-859. https://doi.org/10.2337/dc25-0241